In the News


Zimmer Video


Cook Video

 

NASH

A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice
NuSirt Biopharma and OWL Metabolomics Partner to Advance Treatment of NASH / Non-alcoholic Steatohepatitis
NuSirt announces phase 2 results for leucine/metformin combination in type 2 diabetes; Interview with management on plans in NAFLD/NASH
NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment
NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease
NuSirt Technology Could Aid in Treatment of Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes
Interaction Between Leucine and Phosphodiesterase 5 Inhibition in Modulating Insulin Sensitivity and Lipid Metabolism

Diabetes

NuSirt Biopharma Presenting New Research at American Diabetes Association’s 76th Annual Scientific Sessions
Clinical Trial Results Show Synergy between NuSirt Technology and Metformin in Patients with Type 2 Diabetes
BioWorld – ‘Sirting’ for better control in type 2 diabetes, Nusirt exploits metformin pathway
NuSirt Biopharma Presenting New Data at American Diabetes Association 75th Scientific Sessions
NuSirt Biopharma to Present at American Diabetes Association’s 75th Scientific Sessions
Leucine Amplifies the Effects of Metformin on Insulin Sensitivity and Glycemic Control in Diet-Induced Obese Mice
For NuSirt Biopharma, Less is More
Diabetes in Control Interview with NuSirt CEO Joe Cook, Jr. – Part 1
Diabetes in Control Interview with NuSirt CEO Joe Cook, Jr. – Part 2
Diabetes in Control Interview with NuSirt CEO Joe Cook, Jr. – Part 3
NuSirt Hopes For Diabetes Breakthrough
NuSirt Biopharma Launches First Clinical Trial
Nashville-based pharmaceutical company readies for human trials
NuSirt Biopharma Technology Presented at American Diabetes Association Scientific Sessions
NuSirt Sciences Inc. Working On Diabetes Breakthrough

Corporate Matters

Nashville Post: NuSirt’s Joe Cook Oversees Clinical Trials For Possible Breakthrough Drug
NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease
NuSirt Biopharma Raises $6 Million in Series C Funding
How NuSirt Biopharma hopes to build a life science presence in Nashville

 


Zimmer Video


Cook Video